|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 12:33pm | GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment | MT |
| 09:45am | GSK : DZ Bank remains Neutral | ZD |
| Market Cap | 81.3B 108B 94.91B 88.59B 152B 10,346B 156B 1,051B 411B 5,119B 406B 397B 17,698B | P/E 2026 * |
12.8x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 103B 137B 120B 112B 192B 13,079B 197B 1,328B 519B 6,472B 513B 502B 22,373B | EV / Sales 2026 * |
3.02x | EV / Sales 2027 * | 2.63x |
| Free-Float |
93.18% | Yield 2026 * |
3.43% | Yield 2027 * | 3.61% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | +4.43% | +59.19% | +167.20% | 1,089B | |
| -0.18% | +3.78% | +57.80% | +58.35% | 643B | |
| +1.17% | +4.86% | +38.91% | +77.58% | 465B | |
| -1.69% | +8.81% | +39.38% | +33.67% | 359B | |
| -0.51% | +3.51% | +36.97% | +42.46% | 303B | |
| +1.50% | +3.40% | +17.71% | +17.41% | 267B | |
| +0.79% | +5.81% | -2.55% | -38.10% | 226B | |
| -0.84% | +6.25% | +28.12% | +66.09% | 212B | |
| +0.01% | +2.61% | +17.08% | +75.66% | 167B | |
| Average | +0.03% | +5.07% | +32.51% | +55.59% | 414.57B | |
| Weighted average by Cap. | +0.01% | +5.14% | +42.35% | +81.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 34.03B 45.21B 39.73B 37.08B 63.7B 4,330B 65.27B 440B 172B 2,143B 170B 166B 7,408B | 35.65B 47.36B 41.61B 38.84B 66.73B 4,536B 68.37B 461B 180B 2,245B 178B 174B 7,759B |
| Net income | 6.57B 8.73B 7.67B 7.16B 12.3B 836B 12.6B 84.87B 33.19B 414B 32.76B 32.05B 1,430B | 6.92B 9.2B 8.08B 7.54B 12.96B 881B 13.28B 89.44B 34.98B 436B 34.53B 33.78B 1,507B |
| Net Debt | 21.48B 28.53B 25.07B 23.4B 40.21B 2,733B 41.2B 278B 109B 1,352B 107B 105B 4,675B | 12.47B 16.57B 14.56B 13.59B 23.35B 1,587B 23.93B 161B 63.04B 785B 62.22B 60.87B 2,715B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
